Depression in perimenopause is not simply a response to the difficulty of midlife. It has a distinct biological substrate, a specific epidemiological pattern, and treatment implications that differ from depression at other life stages. These differences affect whether you get the most appropriate treatment.

How Common and When It Peaks

The Study of Women's Health Across the Nation (SWAN), which followed more than 3,300 women aged 42–52 over thirteen years, found that the odds of depressive symptoms increased 1.5 to 2-fold during perimenopause compared to premenopause.[1] The risk peaks in late perimenopause (the one to three years immediately before the final menstrual period) when estrogen is declining most erratically.[1]

A meta-analysis of studies in Chinese perimenopausal women found a depression prevalence of approximately 26%, with mild severity most common.[2] Separate research has consistently found that women with no prior history of depression face a significantly higher risk during the menopausal transition than at any other point in their adult lives.[3]

This is not only a worsening of pre-existing depression, though that also occurs. It is new-onset depression appearing in women who have been mentally well for decades.

Clinical Presentation

Perimenopausal depression does not always present as classic low mood with reduced energy and tearfulness. Research characterises it as having anxious and anhedonic features: a blunting of pleasure and reward rather than profound sadness, often combined with anxiety, irritability, and cognitive complaints.[4]

Women frequently describe it as a loss of their usual sense of themselves. Things that previously brought satisfaction, such as work, relationships, and hobbies, feel flat. Combined with poor sleep and cognitive fog, it can be mistaken for burnout, life dissatisfaction, or a thyroid problem.

Timing is also clinically informative. Perimenopausal depression typically worsens in the premenstrual phase of now-irregular cycles, correlating with hormonal fluctuation rather than a stable low mood throughout the month. This temporal pattern points toward a hormonal driver rather than a purely psychological one.

The Biological Mechanism

Estrogen modulates the GABAergic system (which dampens anxiety), serotonin synthesis and receptor binding, and the HPA axis stress response. When estrogen fluctuates unpredictably, all three of these systems become less stable.

A specific demonstration of the hormonal mechanism comes from a 2015 randomised trial by Schmidt and colleagues, published in JAMA Psychiatry.[5] Women with a history of perimenopausal depression were given stable estradiol levels and then had estradiol withdrawn under controlled conditions. The majority developed significant depressive symptoms in response to the withdrawal. Women without this history did not. This established that susceptibility to estrogen fluctuation, rather than low estrogen per se, is the driver in perimenopausal depression.

Treatment: Why the Context Changes the Approach

For postmenopausal depression with no concurrent hormonal symptoms, standard antidepressants are appropriate and effective. Perimenopausal depression is a different clinical situation.

The evidence supports estradiol as an effective antidepressant during the menopausal transition. A randomised controlled trial using transdermal estradiol (0.1 mg/day) in perimenopausal women with depression found a remission rate of 68% in the estradiol group versus 20% in the placebo group at twelve weeks.[6] The effect appears to be specific to the transition window: the same research group found that estradiol is ineffective as an antidepressant in women well into the postmenopausal period.[7]

This time-specificity is often overlooked. The window during which HRT addresses mood at the hormonal level corresponds to the window when hormonal fluctuation is the active driver. Once the transition is complete and a new equilibrium is established, the mood benefits of HRT differ in character.

Antidepressants remain appropriate options. SNRIs such as venlafaxine and desvenlafaxine have the additional benefit of reducing vasomotor symptoms, making them useful when both mood and hot flashes are significant. For women who cannot or prefer not to use HRT, SSRIs and SNRIs are evidence-based treatments for perimenopausal depression.

The choice between HRT and antidepressants is not binary. Many women benefit from both: addressing the hormonal substrate with estradiol while also using a low-dose antidepressant. The decision should be made with a clinician who understands the specific context of perimenopausal mood, rather than treating it as identical to a first depressive episode in a 30-year-old.

Who Is at Higher Risk

Several factors increase the risk of depression during the menopausal transition:

A history of PMS or PMDD. Women who were sensitive to premenstrual hormonal shifts are more likely to develop perimenopausal depression. The same hormonal sensitivity mechanism operates, now driven by the larger and less predictable fluctuations of perimenopause rather than the monthly cycle.[3]

A prior depressive episode. While perimenopausal depression can be first-onset, a prior history substantially raises the risk of recurrence during the transition.

Significant vasomotor symptoms. Hot flashes and night sweats disrupt sleep, and sleep deprivation is both a consequence and a driver of depression. Depressive mood worsens vasomotor symptoms; vasomotor symptoms worsen sleep and mood.

Stressful life circumstances. The perimenopausal years frequently coincide with caregiving demands, relationship transitions, and career pressures. These compound biological vulnerability.

What to Raise With Your Clinician

If you suspect perimenopausal depression rather than, or in addition to, situational low mood, the following is useful to share:

  • The timing: when during your cycle (even irregular cycles) do symptoms worsen?
  • Whether symptoms correlate with other perimenopausal symptoms, particularly sleep disruption and vasomotor events
  • Any history of PMS, PMDD, or postpartum mood changes
  • Whether anhedonia (loss of pleasure) is a feature alongside low mood

This context helps distinguish hormonally-driven perimenopausal depression from a primary depressive disorder and informs whether estradiol, antidepressants, or a combination is the most appropriate starting point.

References

[1] Bromberger, J. T., Kravitz, H. M., Chang, Y. F., et al. (2011). Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychological Medicine, 41(9), 1879-1888. Cited in: PMC analysis of SWAN depression data. https://pmc.ncbi.nlm.nih.gov/articles/PMC12237151/

[2] Liu, Q., et al. (2023). Risk factors for perimenopausal depression in Chinese women: a meta-analysis. Frontiers in Psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC10598844/

[3] Freeman, E. W., Sammel, M. D., Lin, H., Nelson, D. B. (2006). Associations of hormones and menopausal status with depressed mood in women with no history of depression. Archives of General Psychiatry, 63(4), 375-382. Cited in review: https://pmc.ncbi.nlm.nih.gov/articles/PMC11279181/

[4] Maki, P. M., Kornstein, S. G., Joffe, H., et al. (2019). Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause, 26(2), 181-194. Cited in: Menopause and Mental Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC12237151/

[5] Schmidt, P. J., Ben Dor, R., Martinez, P. E., et al. (2015). Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry, 72(7), 714-726. https://pubmed.ncbi.nlm.nih.gov/26018333/

[6] Soares, C. N., Almeida, O. P., Joffe, H., Cohen, L. S. (2001). Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry, 58(6), 529-534. Cited in: https://pmc.ncbi.nlm.nih.gov/articles/PMC6309886/

[7] Estradiol in perimenopausal depression: so much promise and so few answers. (2019). Current Psychiatry Reports. https://pmc.ncbi.nlm.nih.gov/articles/PMC6309886/

[8] Joffe, H., Groninger, H., Soares, C. N., Nonacs, R., Cohen, L. S. (2001). An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. Journal of Women's Health and Gender-Based Medicine, 10(10), 999-1004. Cited in SSNRIs for co-occurring VMS: https://pmc.ncbi.nlm.nih.gov/articles/PMC12237151/